Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-05 02:01 UTC

BIOMED PULSE

Saturday, September 5, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across 6 provinces, making it the largest Ebola outbreak ever recorded in DRC history — and it is still accelerating. [1] Amid simultaneous Salmonella, Listeria, and food safety alerts, the overall mood today is ELEVATED CONCERN on multiple fronts.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC & UGANDA: HISTORIC AND WORSENING

  • As of August 28, 2026, the Bundibugyo virus disease (BVD) outbreak has spread from 54 to 60 health zones in DRC, now covering Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo provinces — 6 of 26 provinces nationally. [1]
  • WHO's August 14 report called this the largest Ebola outbreak ever reported in DRC and noted it is expanding faster than any previous Ebola outbreak, with sustained transmission as the defining characteristic. [2]
  • The outbreak was first detected May 5, 2026 in Mongbwalu Health Zone, Ituri Province, including deaths among health workers, with Bundibugyo virus confirmed by Institut national de recherche biomédicale on May 14, 2026. [3]
  • By July 15, 2026, cumulative confirmed cases had reached 2,124 with 828 deaths reported from DRC alone; Uganda has also confirmed cross-border transmission. [4]
  • The case fatality burden among confirmed cases has remained severe; the July 3 update recorded 452 deaths among 1,460 confirmed DRC cases. [5]
  • CDC activated enhanced Ebola airport screening at Washington-Dulles International Airport on May 21, 2026, subsequently expanding to Atlanta. [6] [7]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship was first notified to WHO on May 2, 2026; the fifth WHO Disease Outbreak News update was issued July 2, 2026. [8]
  • Initial notification described 7 cases (2 laboratory-confirmed Andes hantavirus, 5 suspected) aboard a ship carrying 147 passengers and crew as of May 4, 2026. [9]
  • CDC issued multiple daily transcript updates through June 24, 2026, signaling ongoing transmission investigation. [10]

MEASLES — BANGLADESH

  • On April 4, 2026, Bangladesh notified WHO of a nationwide measles surge affecting 58 of 64 districts across all 8 divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported.

NIPAH VIRUS — KERALA, INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed case of Nipah virus (NiV) in Kozhikode district; the adult male developed symptoms May 30, 2026, was hospitalized June 10, 2026, and presented with neurological symptoms.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO was notified on March 21, 2026 of a human H9N2 case in an adult male returning from Senegal to Italy; next-generation sequencing confirmed Influenza A(H9N2).

YELLOW FEVER — GLOBAL/AMERICAS

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections, continuing elevated transmission activity that began rising in 2025.

CYCLOSPORIASIS — TACO BELL / ICEBERG LETTUCE, USA

  • CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of Cyclospora infections in 5 states, with 1,644 people reported sick as of July 17, 2026; the outbreak subsequently expanded to 4 additional states.

SALMONELLA — METABOLIC MEALS HOME DELIVERY, USA

  • As of September 5, 2026, 16 people in 10 states have been sickened with the same Salmonella strain linked to Metabolic Meals home delivery foods, with the investigation ongoing.

DRUG-RESISTANT BACTERIA — USA

  • A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in the United States.
  • Separately, an extensively drug-resistant Salmonella outbreak linked to moringa powder capsules was reported February 13, 2026, with 3 hospitalizations and no deaths at that time.

WEST NILE VIRUS — USA

  • CDC reported an early and record-high West Nile season as of the July 4, 2026 holiday weekend, urging the public to take mosquito bite-prevention measures.

🧬 LONGEVITY & AGING

TESTOSTERONE, LONGEVITY, AND REPRODUCTIVE TRADE-OFFS

  • A Mendelian randomization study published in Aging Male (August 17, 2026) by Jiesisibieke and Schooling investigated testosterone's biological trade-offs between longevity and reproductive fitness, using genetic instruments to separate causal effects from confounding.
  • A separate international expert consensus paper in Aging Male (August 26, 2026), authored by 12 specialists including Hackett, Jones, Khera, and Morgentaler, addressed management of testosterone deficiency in primary care settings globally.

SENESCENCE TARGETING — INTERVERTEBRAL DISC DEGENERATION

  • A Biomaterials paper (July 14, 2026) described injectable hydrogel microspheres loaded with senescence-targeting apoptotic extracellular vesicles that mitigate ferroptosis in nucleus pulposus cells, offering a potential strategy against intervertebral disc degeneration — a major cause of disability in older adults.

SENESCENCE IN OSTEOARTHRITIS — DUAL-MODAL THERAPY

  • Published in Bioactive Materials (July 31, 2026), An et al. reported that combining antioxidant and epigenetic approaches synergistically breaks the self-perpetuating senescence cycle in osteoarthritis cartilage, pointing toward combinatorial anti-aging joint therapies.

EGFR LOSS AND FRACTURE HEALING IN AGING

  • A Bioactive Materials study (August 4, 2026) by Hu et al. found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is directly associated with impaired fracture healing in aged mice, identifying EGFR as a therapeutic target for age-related bone repair deficits.

ABCA1 AND AGE-RELATED BONE DEFECTS — mRNA LIPID NANOPARTICLE

  • Cheng et al. in Bioactive Materials (August 20, 2026) demonstrated that a dual-targeting mRNA lipid nanoparticle restoring ABCA1-dependent cholesterol homeostasis in bone cells significantly promoted repair of age-related bone defects in preclinical models.

CALORIE RESTRICTION AND LIFESPAN — SCALLOP TRANSCRIPTOMICS

  • Zhao et al. in Comparative Biochemistry and Physiology (August 10, 2026) used transcriptomics to reveal species-specific adaptive strategies to calorie restriction in two Argopecten scallop species with distinct natural lifespans, illuminating conserved longevity pathways.

HEAT TOLERANCE IN AN AGING WORLD

  • A Lancet Planetary Health modeling study by Kong, Vecellio, Huber et al. projected that exceeding human heat tolerance thresholds will become substantially more common globally as both temperatures and population age increase simultaneously.

DEPRESCRIBING IN OLDER ADULTS

  • Two Lancet Healthy Longevity commentaries by Hwang, Boockvar, and Steinman, and by Van der Linden, called for a rationale-first framework before selecting trial design in deprescribing research — relevant as polypharmacy remains a major driver of adverse outcomes in older populations.

ANESTHESIA FOR HIP FRACTURE IN OLDER PATIENTS

  • A multicentre randomized clinical trial published in Lancet Healthy Longevity (Kowark et al., Germany) compared spinal versus general anesthesia for serious complications in older patients undergoing hip fracture surgery, a topic of major clinical importance given fracture rates in aging populations.

UROLITHIN A AND GLUCOSE METABOLISM — CLINICAL TRIAL

  • ClinicalTrials.gov (NCT06274749, updated September 4, 2026) is running a randomized triple-masked controlled trial of Urolithin A (UA) supplementation on glucose metabolism in healthy adults aged 55 and older, targeting the age-related decline in pancreatic insulin secretion.

NICOTINAMIDE RIBOSIDE (NR) AND METABOLIC RATE — CLINICAL TRIAL

  • NCT06044935 (updated September 4, 2026) is testing how nicotinamide riboside (NR), an NAD+ precursor, combined with a low-carbohydrate diet, affects ketosis, fat oxidation, and metabolic rate, with implications for fatty liver disease affecting at least 30% of Americans.

METFORMIN DELIVERY TO JOINTS — OSTEOARTHRITIS NANOPARTICLE

  • Han et al. in Biomaterials (July 6, 2026) developed a dual-engineered chondrocyte-targeting tetrahedral DNA-based nanoparticle for improved joint delivery of metformin, demonstrating alleviation of osteoarthritis — repurposing a longevity-associated drug via precision delivery.

💊 NEW CURES & APPROVALS

MIMRYLO (RUSFERTIDE ACETATE) — TAKEDA PHARMACEUTICALS U.S.A., INC.

  • Takeda received an original FDA approval (NDA220605) for Mimrylo, active ingredient rusfertide acetate, a hepcidin mimetic indicated for polycythemia vera (a blood disorder causing overproduction of red blood cells).

UNLOXCYT (COSIBELIMAB-IPDL) — CHECKPOINT THERAPEUTICS INC.

  • Checkpoint Therapeutics received a supplemental FDA approval (BLA761297) for Unloxcyt (cosibelimab-ipdl), a PD-L1 checkpoint inhibitor, expanding its use.

YERVOY (IPILIMUMAB) — BRISTOL MYERS SQUIBB

  • Bristol Myers Squibb received a supplemental FDA approval (BLA125377) for Yervoy (ipilimumab), the CTLA-4 immune checkpoint inhibitor used in multiple cancers.

LIBTAYO (CEMIPLIMAB-RWLC) — REGENERON PHARMACEUTICALS

  • Regeneron received a supplemental approval (BLA761097) for Libtayo (cemiplimab-rwlc), a PD-1 inhibitor with indications in skin and other cancers.

IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD

  • AstraZeneca UK received a supplemental FDA approval (BLA761069) for Imfinzi (durvalumab), a PD-L1 checkpoint inhibitor used in lung and biliary tract cancers.

IMJUDO (TREMELIMUMAB-ACTL) — ASTRAZENECA AB

  • AstraZeneca AB received a supplemental approval (BLA761289) for Imjudo (tremelimumab-actl), a CTLA-4 inhibitor used in combination regimens for hepatocellular carcinoma and non-small cell lung cancer.

LOQTORZI (TORIPALIMAB-TPZI) — COHERUS BIOSCIENCES INC.

  • Coherus Biosciences received a supplemental FDA approval (BLA761240) for Loqtorzi (toripalimab-tpzi), a PD-1 inhibitor indicated in nasopharyngeal carcinoma.

BAVENCIO (AVELUMAB) — EMD SERONO INC.

  • EMD Serono received a supplemental FDA approval (BLA761049) for Bavencio (avelumab), a PD-L1 inhibitor used in Merkel cell carcinoma and urothelial carcinoma.

PENPULIMAB-KCQX — AKESO BIOPHARMA

  • Akeso Biopharma received a supplemental FDA approval (BLA761258) for penpulimab-kcqx, a PD-1 inhibitor for nasopharyngeal carcinoma.

POMALIDOMIDE GENERICS — SANDOZ AND CIPLA

  • Both Sandoz (ANDA220741) and Cipla (ANDA219718) received original FDA approvals for generic pomalidomide, an immunomodulatory agent used in relapsed/refractory multiple myeloma, significantly expanding patient access.

🧪 CLINICAL TRIALS

KarXT FOR ALZHEIMER'S PSYCHOSIS — PHASE 3 (ADEPT-2, NCT06126224)

  • The Phase 3 ADEPT-2 trial, updated September 4, 2026, is evaluating KarXT (xanomeline-trospium, an M1/M4 muscarinic receptor agonist combination) versus placebo in adults aged 55-90 with mild-to-severe Alzheimer's disease and moderate-to-severe psychosis; primary endpoint is psychosis severity reduction.

VENETOCLAX + ASTX727 FOR AML IN ELDERLY PATIENTS (NCT04746235)

  • This Phase II trial, updated September 4, 2026, studies venetoclax (BCL-2 inhibitor) combined with ASTX727 (decitabine/cedazuridine, an oral hypomethylating agent) in relapsed/refractory AML and in newly diagnosed elderly AML patients ineligible for intensive chemotherapy.

UROLITHIN A IN ADULTS 55+ — GLUCOSE METABOLISM (NCT06274749)

  • Randomized triple-masked controlled trial testing whether Urolithin A, a gut-microbiome-derived mitophagy activator, improves insulin secretion and blood glucose control in healthy adults 55 years and older.

NICOTINAMIDE RIBOSIDE (NR) — METABOLIC RATE AND FAT OXIDATION (NCT06044935)

  • Trial testing NR supplementation's effect on ketosis and fat oxidation in individuals with fatty liver disease, targeting the NAD+ depletion pathway associated with metabolic aging.

TAPISTRY PLATFORM — TUMOR-AGNOSTIC IMMUNO-ONCOLOGY (NCT04589845)

  • Roche's Phase II global multicenter open-label platform study evaluates targeted therapies and immunotherapy as single agents or combinations in participants with unresectable locally advanced or metastatic solid tumors defined by biomarker profiles, updated September 4, 2026.

LIFESTYLE INTERVENTION FOR HEALTH MAINTENANCE (NCT07314957)

  • Randomized controlled trial evaluating the impact of structured physical activity programs and nutrition education on healthy lifestyle habits and health outcomes over time in at-risk populations, updated September 4, 2026.

FOSTAMATINIB IN LUNG TRANSPLANT — DONOR ANTIBODY REJECTION (SIMILAR, NCT06948097)

  • The SIMILAR trial, updated September 4, 2026, assesses safety and tolerability of fostamatinib (a Syk kinase inhibitor) in lung transplant patients who develop donor-specific antibodies — a leading cause of allograft failure and shortened post-transplant survival.

MYOTONIC DYSTROPHY TYPE 1 BIOMARKERS (END-DM1 EXTENSION, NCT07700225)

  • Extension study establishing biomarkers and clinical endpoints for DM1, a multisystemic disorder with progressive disability and shortened life expectancy, updated September 4, 2026.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK — EXPANDED TO MORE PREPARED FOODS

  • CDC expanded its Listeria monocytogenes outbreak alert on September 26, 2025 to include additional prepared meals; 3 additional illnesses and 1 additional death were reported in that update, and CDC continued urging consumers to check refrigerators and freezers for recalled foods through October 30, 2025.

SYPHILIS IN NEWBORNS — 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data released September 24, 2025 showed U.S. cases of newborn (congenital) syphilis increased for the 12th consecutive year in 2024, signaling persistent STI epidemic gaps.

DRUG-RESISTANT BACTERIA — SHARP RISE

  • CDC's September 23, 2025 report documented a dramatic increase in a dangerous class of drug-resistant bacteria in U.S. healthcare settings, reinforcing antimicrobial resistance as an urgent public health priority.

WEST NILE EARLY SEASON WARNING — USA

  • CDC on July 1, 2026 warned of a record early West Nile virus season, urging Americans to use insect repellent and eliminate standing water to reduce mosquito exposure during peak summer activity.

TIMOR-LESTE CERTIFIED MALARIA-FREE — WHO

  • WHO certified Timor-Leste as malaria-free on July 24, 2025, recognizing the country's sustained nationwide elimination program launched after independence in 2002.

U.S. WITHDRAWAL FROM WHO COMPLETED

  • The United States formally completed its WHO withdrawal on January 22, 2026; WHO issued a statement on January 24, 2026 warning the decision "makes both the United States and the world less safe."

NOTE: BIOMED PULSE is an informational briefing only and does not constitute medical advice. Consult qualified healthcare professionals for medical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  10. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260905-02-v66 · 2026-09-05 02:01 UTC · pulse.uzylab.com

Read next